This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Why the Market Dipped But Pfizer (PFE) Gained Today
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $25.91, moving +0.19% from the previous trading session.
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
by Kinjel Shah
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
by Zacks Equity Research
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
by Zacks Equity Research
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
The Zacks Analyst Blog Highlights UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International
by Zacks Equity Research
UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International are part of the Zacks top Analyst Blog.
Top Analyst Reports for UnitedHealth, Pfizer & BlackRock
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including UnitedHealth Group Incorporated (UNH), Pfizer Inc. (PFE) and BlackRock, Inc. (BLK).
Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal
by Zacks Equity Research
Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.
Pfizer (PFE) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $26.58, marking a -0.3% move from the previous day.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Pfizer (PFE) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $27.72, marking a -0.11% move from the previous day.
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
by Zacks Equity Research
Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $27.43, moving +0.26% from the previous trading session.
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
by Zacks Equity Research
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
by Kinjel Shah
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
by Zacks Equity Research
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
by Zacks Equity Research
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Pfizer (PFE) closed at $27.63 in the latest trading session, marking a -0.32% move from the prior day.
Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%
by Zacks Equity Research
Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.
The Zacks Analyst Blog Highlights Microsoft, Coca-Cola, Accenture, Applied Materials and Pfizer
by Zacks Equity Research
Microsoft, Coca-Cola, Accenture, Applied Materials and Pfizer are included in this Analyst Blog.